Evidence map›Paper›PMID 25211390›Full record

ArticleAnesthesia and analgesia2014

Enhancement of α5-containing γ-aminobutyric acid type A receptors by the nonimmobilizer 1,2-dichlorohexafluorocyclobutane (F6) is abolished by the β3(N265M) mutation.

Paul M Burkat, Chong Lor, Misha Perouansky, Robert A Pearce

Open access · greenAbstract read
In one paragraph

Article in Anesthesia and analgesia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Isoflurane Potentiation of GABAInternational journal of molecular sciences · 2020
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 3 countries.

Paul M BurkatFrom the Department of Anesthesiology, University of Wisconsin SMPH, Madison, Wisconsin.
Chong Lor
Misha Perouansky
Robert A Pearce
University of Wisconsin–Madison · US

Funding

SITES AND MECHANISMS OF INHALED ANESTHETIC ACTIONSP01GM047818 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SONNER, JAMES MICHAEL · 1994 to 2008
$11.0M
VOLATILE ANESTHETIC ACTIONS ON SYNAPTIC GABAA RECEPTORSR01GM055719 · NIGMS · UNIVERSITY OF WISCONSIN MADISON · PI PEARCE, ROBERT A · 1997 to 2005
$1.8M
NIGMS NIH HHS GM47818NIGMS NIH HHS GM55719NIGMS NIH HHS P01 GM047818NIGMS NIH HHS R01 GM055719
6 · The paper itself

Abstract

backgroundModulation of γ-aminobutyric acid type A receptors (GABAARs) by general anesthetics may contribute to their ability to produce amnesia. Receptors containing α5 subunits, which mediate tonic and slow synaptic inhibition, are co-localized with β3 and γ2 subunits in dendritic layers of the hippocampus and are sensitive to low (amnestic) concentrations of anesthetics. Because α5 and β3 subunits influence performance in hippocampus-dependent learning tasks in the presence and absence of general anesthetics, and the experimental inhaled drug 1,2-dichlorohexafluorocyclobutane (F6) impairs hippocampus-dependent learning, we hypothesized that F6 would modulate receptors that incorporate α5 and β3 subunits. We hypothesized further that the β3(N265M) mutation, which controls receptor modulation by general anesthetics, would similarly influence modulation by F6.

methodsUsing whole-cell electrophysiologic recording techniques, we tested the effects of F6 at concentrations ranging from 4 to 16 μM on receptors expressed in human embryonic kidney 293 cells. We measured drug modulation of wild-type α5β3 and α5β3γ2L GABAARs and receptors harboring the β3(N265M) mutation. We also tested the effects of F6 on α1β2γ2L receptors, which were reported previously to be insensitive to this drug when expressed in Xenopus oocytes.

resultsF6 enhanced the responses of wild-type α5β3γ2L but not α1β2γ2L receptors to low concentrations of GABA in a concentration-dependent manner. Receptors that incorporated the mutant β3(N265M) subunit were insensitive to F6. When applied together with a high concentration of GABA, F6 blocked currents through α5β3 but not α5β3γ2L receptors. F6 did not alter deactivation of α5β3γ2L receptors after brief high- concentration pulses of GABA.

conclusionsThe nonimmobilizer F6 modulates GABAARs in a manner that depends on subunit composition and mode of receptor activation by GABA, supporting a possible role for α5-containing receptors in suppression of learning and memory by F6. Furthermore, common structural requirements indicate that similar molecular mechanisms may be responsible for the enhancing effects of F6 and conventional general anesthetics.

Indexed as

MutationAnestheticsChlorofluorocarbonsCyclobutanesDose-Response Relationship, DrugGABA Modulatorsgamma-Aminobutyric AcidHEK293 CellsHumansKineticsMembrane PotentialsReceptors, GABA-A1,2-dichloro-1,2,3,3,4,4-hexafluorocyclobutaneAnestheticsChlorofluorocarbonsCyclobutanesGABA ModulatorsGABRA5 protein, humanGABRB3 protein, humanGABRG2 protein, humangamma-Aminobutyric AcidReceptors, GABA-A

Identifiers

PMID25211390
PMCPMC4237654
OpenAlexW2320475922

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.